Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 291 · FY2023 2,264 · FY2024 375 — 3-yr total 2,930
Pharmacy chain/pharmaceuticals distributor operating in Georgia.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 182 | 33 | 1,690 | 1,966 | 2,355 | 611 | 926 | +31.2% |
| Net Cash used in Investing Activities | 0 | 0 | 118 | 75 | 412 | 119 | 678 | +54.7% |
| Free Cash Flow (OCF − Capex proxy) | 182 | 33 | 1,572 | 1,891 | 1,943 | 493 | 248 | +5.3% |
| Net Cash from Financing Activities | 0 | 0 | 1,231 | 502 | 266 | 2,426 | 390 | -25.0% |
| Net Change in Cash (before FX) | 182 | 33 | 341 | 1,389 | 1,677 | 1,933 | 142 | nmf |
| Effect of FX on Cash | 0 | 0 | 17 | 79 | 265 | 30 | 11 | nmf |
| Net Change in Cash (incl. FX) | 182 | 33 | 324 | 1,310 | 1,412 | 1,964 | 131 | nmf |
| Cash at Beginning of Year | 112 | 294 | 328 | 652 | 1,962 | 3,374 | 1,410 | +52.4% |
| Cash at End of Year | 294 | 327 | 652 | 1,962 | 3,374 | 1,410 | 1,279 | +27.8% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →